id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1368488,addacb28-6dbf-4ea2-9af1-1c830fc52cea,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2013,first_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,111725,0,0,2013-04-01T11:54:32.130000-04:00
1369234,d15d1944-6d6b-4b94-9a3c-4cc502798711,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2013,first_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         
Collaborative research on drug development                                
Human factors research related to neuropharmaceuticals","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)",,29312,0,0,2013-04-08T11:14:59.307000-04:00
1369386,b000f88c-25cf-4d11-877b-7f516f9d81e7,Q1,MR. VINCENT A. PANVINI,401008845,PHRMA,2013,first_quarter,PHA,"Medicare Part D, Transpacific Partnership (TPP)","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2013-04-08T15:12:22.777000-04:00
1369478,4b750e50-de92-4684-985e-71e51e38952f,Q1,VENABLE LLP,39941,ENDO PHARMACEUTICALS INC,2013,first_quarter,PHA,Issues related to tamper resistant formulation of pharmaceuticals drugs. The Life Sciences Jobs and Investment Act.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-08T16:34:02.147000-04:00
1369813,2fcb48b9-c4bc-4314-a58f-52c766e22719,Q1,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2013,first_quarter,PHA,"HR 8, Fiscal Cliff Bill, Diabetic Testing Supplies Provisions; S.644, The Preventing Abuse of Cough Treatments Act of 2013; HR 1285, Making Hydrocodne Schedule II; S. 621, THe Safe Prescribing Act of 2013; HR 1024, The Medication Therapy Management Empowerment Act of 2013; S. 557, The Medication Therapy Management Empowerment Act of 2013; HR 1188, The Preserving our Hometown Independent Pharmacies Act of 2013 SEE ADDENDUMPharmaceutical Supply Chain Security Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in the National Defense Authorization Act; Deficit Reduction Issues; Pharmacy Preferred Networks issues","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE",,250000,0,0,2013-04-09T16:31:30.740000-04:00
1369844,0dcb0dd8-fdc0-4563-a3ba-8050af284c1c,1A,MR. VINCENT A. PANVINI,401008845,ELI LILLY AND COMPANY,2013,first_quarter,PHA,"Medicare Part D, Transpacific Partnership","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-09T20:52:51.587000-04:00
1370015,659dcbf3-b858-4566-b129-ff0dfbff6dfd,Q1,"VORYS ADVISORS, LLC",400873558,AMERISOURCEBERGEN CORPORATION,2013,first_quarter,PHA,Various health care proposals,HOUSE OF REPRESENTATIVES,,,0,0,2013-04-10T11:35:35.093000-04:00
1370051,eb2cdc25-d254-4b3a-b873-79caefbf545b,Q1,"DUTKO WORLDWIDE, LLC",12868,NEWAYS INTERNATIONAL,2013,first_quarter,PHA,"Monitor legislation pertaining to dietary supplements and pharmaceuticals, particularly the Food Safety Modernization Act (PL 111-353) and Patient Protection and Affordable Care Act (PL 111-148).","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2013-04-10T11:59:54.500000-04:00
1370137,feade8d9-b3d0-4607-b0b7-5cc3a7bc6967,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,ASTRAZENECA PHARMACEUTICALS LP,2013,first_quarter,PHA,Issues realted to access to pharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-10T12:52:50.307000-04:00
1370241,fe61eff3-bc25-41a3-b7ad-ea69144d354c,Q1,MCDERMOTT WILL & SCHULTE LLP,24338,"ALLERGAN, INC.",2013,first_quarter,PHA,Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2013-04-10T14:38:08.220000-04:00
1370423,fcd37c9d-f6a9-4c9f-a007-1677690c09f6,1T,"MERCURY PUBLIC AFFAIRS, LLC",70175,EXPRESS SCRIPTS INC.,2013,first_quarter,PHA,Prescription drug monitoring.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,1,2013-04-10T16:48:51.917000-04:00
1370474,893fbb49-c781-4729-bbf8-5116ff96e2dc,Q1,INJURED WORKERS PHARMACY,400765309,INJURED WORKERS PHARMACY,2013,first_quarter,PHA,Transparency of Pharmacy Benefit Managers (bill sponsored by Rep. McMorris-Rodgers and Senator Mark Pryor); Longshoreman and Harbor Workers Amendment Act of 2011 sponsored by Senator Isakson.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-11T09:16:24.133000-04:00
1370742,6ee35984-417e-41bc-a8df-567f5172e7b1,Q1,UPS (UNITED PARCEL SERVICE),39223,UPS (UNITED PARCEL SERVICE),2013,first_quarter,PHA,- HR 2405 / S.1855 Healthcare Supply Chain Safety - track and trace in the Prescription Drug Users Fee Act,"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Joint Chiefs of Staff,Labor, Dept of (DOL),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office",,1427716,0,0,2013-04-11T14:05:35.967000-04:00
1371271,3b302417-cd62-4531-a699-0e92a20fc1d7,Q1,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2013,first_quarter,PHA,"Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE",,260000,0,0,2013-04-12T16:32:45.613000-04:00
1371503,466679d2-c639-4cd8-a44a-2fef9f34b481,Q1,"HEARTLAND SOLUTIONS GROUP, INC.",312133,ZEBRA TECHNOLOGIES CORPORATION,2013,first_quarter,PHA,"Any and all issues related to barcode, secure identification and real-time location systems.","HOUSE OF REPRESENTATIVES,SENATE",48000,,0,0,2013-04-14T18:36:38.783000-04:00
1371733,3ccbbed5-1798-4cad-b9a8-286dd62b918e,Q1,"OMNICARE, INC.",321112,OMNICARE INC,2013,first_quarter,PHA,Drug Enforcement Administration proposed rule on disposal of controlled substances in long term care facilities.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2013-04-15T11:07:47.140000-04:00
1371975,f1189876-16e6-4dde-b8dc-709c20dc7a5c,Q1,ANIMAL HEALTH INSTITUTE,4037,ANIMAL HEALTH INSTITUTE,2013,first_quarter,PHA,Issues related to pharmacy compounding; veterinary Drug Enforcement Administration issues - Veterinary Medicine Mobility Act of 2013.,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",,55000,0,0,2013-04-15T12:52:25.743000-04:00
1372281,a1f3a54d-79e0-4b72-98c1-bb04954e7577,Q1,"NAHIGIAN STRATEGIES, LLC",322897,TEVA PHARMACEUTICALS USA INC,2013,first_quarter,PHA,"Generic pharmaceutical issues, including patent settlements, and regulatory.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-15T14:33:08.317000-04:00
1372383,acfe7cf1-d80e-4d50-a5d1-54cfd3c1e769,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"POZEN, INC.",2013,first_quarter,PHA,To provide incentives for new drug development.  No specific bills pending.,"HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2013-04-15T15:03:20.263000-04:00
1372463,196238f4-99e8-4c55-9ef4-85675abc3fe8,Q1,"SHELTER ROCK STRATEGIES, LLC",400772326,NEW YORK MEDICAL COLLEGE,2013,first_quarter,PHA,"BARDA Solicitation HHS 11-100SOL-00011, Centers for Innovation in Advanced Development and Manufacturing, Assess the likelihood this solicitation will get funded, assess competition, assist in writing and getting signed memoranda of support from the New York Congressional Delegation, and assist in obtaining support from New York State to aide the client's proposal.",SENATE,,,0,0,2013-04-15T15:40:56.047000-04:00
1373390,191f222c-deda-42e8-9651-4011daf45bf2,Q1,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2013,first_quarter,PHA,Issues regarding Pharmaceutical Traceability Enhancement Code (Rx TEC) Act and discussion draft on serialization (track and trace); S.622 -- Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 for amendments that would impact human drug user fees; issues regarding biosimilars; 340B,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,600000,0,0,2013-04-16T14:29:05.360000-04:00
1373440,c13d871a-7f47-42a2-8dff-2ab9a99c2203,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"BRAIDWOOD MANAGEMENT, INC.",2013,first_quarter,PHA,Issues related to the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2013-04-16T14:47:26.453000-04:00
1373461,f23dcbd8-9a87-49c9-b23f-fba879446b4f,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,DIAMONDBACK DRUGS,2013,first_quarter,PHA,Issues related to the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.,"HOUSE OF REPRESENTATIVES,SENATE",6000,,0,0,2013-04-16T14:53:33.417000-04:00
1373476,5b3485a2-bc54-48cf-9cc9-2966d22c8d60,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"VETERINARY PHARMACIES OF AMERICA, INC.",2013,first_quarter,PHA,Issues related to the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2013-04-16T15:00:39.710000-04:00
1373499,7bac7818-33e5-48ed-9aee-974b1255923c,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WEDGEWOOD VILLAGE PHARMACY, INC.",2013,first_quarter,PHA,Issues related to the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2013-04-16T15:07:50.657000-04:00
1373530,6c4143a5-3893-4102-b38c-3f527702f812,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2013,first_quarter,PHA,Issues related to the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2013-04-16T15:12:59.027000-04:00
1373618,4b52c97c-df0b-4719-aee2-4a278ee35e1d,Q1,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2013,first_quarter,PHA,"H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy

Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation.

Policies related to stopping the diversion of prescription medications in the nation's drug supply chain.

Changes in International Naming policies for generic medications.","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-04-16T15:44:37.750000-04:00
1373661,1d7c3629-aba5-40d8-b420-cf093f0ff80b,Q1,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2013,first_quarter,PHA,"Rx Pedigree; Prescription Drug Monitoring Programs; Drug Abuse (S. 348), Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644); Drug Shortages; Counterfeit Drugs; Importation of Prescription Drugs","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,286000,0,0,2013-04-16T16:02:50.927000-04:00
1373708,6953e519-86f6-4216-a34c-9748518a2577,Q1,"AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)",1581,AMERICA'S HEALTH INSURANCE PLANS INC (AHIP),2013,first_quarter,PHA,"H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act16.  Specific Lobbying Issues (continued):
(Lynch)  FEHBP prescription drugs 
S. 214, Preserve Access to Affordable Generics Act (Klobuchar)  access to generic drugs 

Regulatory Issues:
Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Bureau of Investigation (FBI),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Pension & Welfare Benefits Administration,SENATE,Treasury, Dept of,White House Office",,2490000,0,0,2013-04-16T16:32:19.323000-04:00
1373716,6f53ad81-089a-437b-b038-59fb1a6fcb61,Q1,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2013,first_quarter,PHA,Tax Payer Relief Act 2013 Implementation of Diabetic Supply Reimbursement Changes,Centers For Medicare and Medicaid Services (CMS),,,0,0,2013-04-16T16:35:25.167000-04:00
1373850,31728ec1-8c70-4bdd-a4cf-1cdc5b3eea31,Q1,CAPITOL HILL CONSULTING GROUP,72053,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2013,first_quarter,PHA,Compounding pharmacy and FDA issues,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-16T17:28:16.090000-04:00
1373974,d8b45cf6-d5e5-4771-95d8-8f06b48be2f7,Q1,THE INGRAM GROUP LLC,400577737,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2013,first_quarter,PHA,"Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-04-16T22:37:03.437000-04:00
1374059,8215a15a-b6fe-4d37-8ebb-9a0288ac76dd,Q1,"MEHLMAN CONSULTING, INC.",284950,PROCTER & GAMBLE,2013,first_quarter,PHA,Preventing Abuse of Cough Treatments Act of 2013 (S. 644),"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-17T09:33:34.577000-04:00
1374470,4acb5b81-b484-4afb-96e3-cd785ee576f0,Q1,COVIDIEN LP,319778,COVIDIEN LP,2013,first_quarter,PHA,Issues involving controlled substances and pain and addiction drugs generally.,"Energy, Dept of,Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS)",,720000,0,0,2013-04-17T11:43:57.443000-04:00
1374555,ef9208bf-c470-4a5f-b036-deb82045a15e,Q1,ACG ADVOCACY,2057,GENENTECH INC,2013,first_quarter,PHA,Tamiflu.,"HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)",40000,,0,0,2013-04-17T12:00:34.867000-04:00
1374703,831d177d-15d3-45d6-8dfb-b71e3e1e8dc0,Q1,CAPITOL HILL CONSULTING GROUP,72053,PURDUE PHARMA LLP,2013,first_quarter,PHA,"Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)","HOUSE OF REPRESENTATIVES,SENATE",47000,,0,0,2013-04-17T12:34:47.713000-04:00
1374767,680308e7-cbb8-4c34-afe0-115e98048057,Q1,"CYBER SECURITY RESEARCH CONSULTANTS, LLC",91694,PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2013,first_quarter,PHA,Monitoring drug importation legislation,SENATE,21000,,0,0,2013-04-17T12:50:23.843000-04:00
1375233,9be52443-0233-464e-9cc1-65c5947a682c,Q1,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2013,first_quarter,PHA,Contact concerning Food and Drug Administration (FDA) authority to manage drug shortages. Communication to FDA on Drug Shortages Task Force. Communication with Drug Enforcement Administration (DEA) on Central Fill of Controlled Substances. Communication with FDA and Center for Disease Control and Prevention on compounding.,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,250000,0,0,2013-04-17T14:54:24.027000-04:00
1375436,c1bf12a6-c427-454e-970a-e57680c154ce,Q1,HAAKE & ASSOCIATES,17226,JOHNSON & JOHNSON SERVICES INC.,2013,first_quarter,PHA,Policy and procurement matters related to vaccines,"Air Force, Dept of,Army, Dept of (Other),Defense, Dept of (DOD),Defense Logistics Agency,Navy, Dept of,U.S. Marines",20000,,0,0,2013-04-17T15:33:54.123000-04:00
1375589,966d9413-5a33-4057-9011-f9c2138f12b7,Q1,"THE OB-C GROUP, LLC",29802,ELI LILLY,2013,first_quarter,PHA,No specific bill number: matters relating to pharmaceutical manufacturers and Medicare Part D.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2013-04-17T16:05:51.720000-04:00
1375611,affca1e2-338d-4145-b3ac-128ae2fe7a7d,Q1,"NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC",400689052,WOCKHARDT USA LLC,2013,first_quarter,PHA,Issues affecting settlement of litigation between NDA and ANDA holders,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-17T16:15:00.197000-04:00
1375912,1542b2f9-ed13-44f0-93c1-874a3f9e2349,1T,"C2 GROUP, LLC",66693,AMERICAS HEALTH INSURANCE PLANS (AHIP),2013,first_quarter,PHA,"H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2013-04-17T19:22:13.410000-04:00
1375995,f4a53cfa-cda2-4bf6-b976-0e9964bd89a5,Q1,THORN RUN PARTNERS,400534596,LONG TERM CARE PHARMACY ALLIANCE,2013,first_quarter,PHA,"Issues related to short-cycle dispensing.
Issues related to PBM audit legislation.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-17T22:20:20.713000-04:00
1376028,f4375d11-a70c-42a5-bee2-0d1629b3a0fb,1T,"C2 GROUP, LLC",66693,PERRIGO INC,2013,first_quarter,PHA,"OTC medication eligibility under Flexible Spending Accounts, S.312/H.R.605, The Patients' Freedom to Choose Act; Drug Regulation; FDA reform; PDUFA, H.R.3630. Pharmaceutical traceability. Rx OTC switch. Rx TEC. GDUFA H.R.5651, S.3187. Fairness to Pet Owners Act.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2013-04-17T22:54:33.513000-04:00
1376173,a619ba6f-dd65-4403-b469-e7dfaad75687,Q1,"PD FRAZER CONSULTING, INC.",65998,CANADA INTERNATIONAL PHARMACY ASSOCIATION,2013,first_quarter,PHA,Monitor the development of proposed bills about the importation of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2013-04-18T08:48:42.397000-04:00
1376175,a941e1d2-d0a5-4678-b894-02161657b9d0,Q1,"WEXFORD STRATEGIC ADVISORS, INC.",401047947,"P.D. FRAZER CONSULTING, INC., CANADIAN INTERNATIONAL PHARMACY ASSOCIATION",2013,first_quarter,PHA,Monitor the development of proposed bills about the importation of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2013-04-18T08:52:43.657000-04:00
1376395,0d6d6a0f-0a8d-441f-8619-0c42dddabbae,Q1,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2013,first_quarter,PHA,Any legislation related to the 340B Drug Discount Program or changes contemplated by members of Congress.,"HOUSE OF REPRESENTATIVES,SENATE",,58855,0,0,2013-04-18T10:36:21.467000-04:00
1376700,98d71c84-d06d-4740-84f9-cb2fdf3dc7fd,Q1,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,26672,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2013,first_quarter,PHA,"S.644, Preventing Abuse of Cough Treatments Act of 2013
S. 621, Safe Prescribing Act of 2013
H.R. 1285, Safe Prescribing Act of 2013","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,660000,0,0,2013-04-18T11:28:09.707000-04:00
1376808,52119da8-98f1-48b9-8831-f8b16482d970,Q1,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2013,first_quarter,PHA,"Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.H.R. 933  - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries.

H.R. 307 - Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 - Focus on the potential for language that would allow for greater focus on the need for new antibiotics to enter into the pipeline.

Continued work on issues related to downstream supply chain safety of prescription medications

Issues related to safety in compounding of certain medications","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-18T11:57:52.613000-04:00
1376827,cdc48891-dbb4-452f-893e-467a014875a7,Q1,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2013,first_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including drug shortage legislation, implementation of P.L. 112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs);  issues related to drug compounding oversight by Congress; 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance (FDA-2011-D-0530).","Centers For Medicare and Medicaid Services (CMS),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),SENATE,White House Office",,260000,0,0,2013-04-18T12:06:03.280000-04:00
1376883,5b35c265-043f-4d32-bd1b-70c682951925,Q1,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2013,first_quarter,PHA,Hospital discounts (HR 3590),"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,2610000,0,0,2013-04-18T12:17:27.833000-04:00
1376959,61589511-53c5-4543-a6b7-e3bc58fc99e1,Q1,"NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC)",85071,UNITED PARCEL SERVICE,2013,first_quarter,PHA,"Issues related to the security and integrity of the domestic pharmaceutical distribution system. 
HR 2405 and S.1855 - Healthcare Supply Chain Safety - track and trace in the Prescription Drug Users Fee Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-18T12:28:59.743000-04:00
1376974,5ff451e6-f326-49a0-9b5f-8ca21a8a6903,Q1,"EXPRESS SCRIPTS, INC.",294416,"EXPRESS SCRIPTS, INC.",2013,first_quarter,PHA,"Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).   General issues dealing with prescription drug abuse.  General issues dealing with pharmacy drug compounding.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,White House Office",,445817,0,0,2013-04-18T12:32:05.383000-04:00
1377223,dd1d63eb-c05d-4861-8e14-346cb21f8927,1A,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2013,first_quarter,PHA,"Rx Pedigree; Prescription Drug Monitoring Programs; Drug Abuse (S. 348), Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644); Drug Shortages; Counterfeit Drugs; Importation of Prescription Drugs","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,286000,0,0,2013-04-18T13:32:34.460000-04:00
1377245,5ea54ade-f394-420f-bd47-65556ae02a08,Q1,BROWN RUDNICK LLP,287895,HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC,2013,first_quarter,PHA,"issues relating to pharmaceutical pedigree.
S. 621 & H.R. 1285 - Safe Prescribing Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-18T13:35:41.523000-04:00
1377749,61b7ecc4-4f8e-40de-8213-63b8d20ba1c4,Q1,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,3446,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,2013,first_quarter,PHA,"S. 1560 (the Nursing Home Resident Pain Relief Act of 2011), implementation of electronic health records and health information technology","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-18T14:46:12.823000-04:00
1378152,a1eb6896-66ac-4046-bc01-63bc8546d213,Q1,KATE MOSS,25988,CVS HEALTH,2013,first_quarter,PHA,Issues related to prescription drug abuse and drug supply chain safety.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2013-04-18T15:23:39.090000-04:00
1378176,a89bad4b-3233-47a9-9adc-f398bd19b1e1,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2013,first_quarter,PHA,Issues related to drug shortages.,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2013-04-18T15:27:51.757000-04:00
1378198,844375e8-2c4d-4828-8ad9-fab052a17775,1A,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2013,first_quarter,PHA,Issues related to drug shortages.,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2013-04-18T15:31:00.130000-04:00
1378263,a8a14566-3e86-4c39-82f4-fcc85aace882,Q1,PHILIP W. JOHNSTON ASSOCIATES,400278335,LUMARA HEALTH (FKA KV PHARMACEUTICAL COMPANY),2013,first_quarter,PHA,Legislation regulationg compounding pharmacies to improve patient safety.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2013-04-18T15:36:19.487000-04:00
1378278,b810955c-1412-4900-87ae-83bc9133611a,Q1,"WHITMER & WORRALL, LLC",292892,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2013,first_quarter,PHA,Issues related to monitoring healthcare reform.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-18T15:38:25.967000-04:00
1378304,6b1b406c-d5c0-48c6-9484-b9ff3b372b1f,Q1,FAEGRE BAKER DANIELS CONSULTING,34158,ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP),2013,first_quarter,PHA,Online pharmacies - S. 2002 and HR 4095,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-18T15:43:40.357000-04:00
1378384,9ce3b964-3ef0-4152-892f-f2b9c186a93a,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2013,first_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2013-04-18T15:53:17.193000-04:00
1378447,da12160a-3ea3-4c4b-9026-3fec48d51afd,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2013,first_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. 
HR 460 - Patients Access to Treatment Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2013-04-18T15:58:41.140000-04:00
1378463,2956a738-497c-48b6-9114-6ebc90ff58ff,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2013,first_quarter,PHA,Issues realted to the 340B drug discount program.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-18T15:59:50.640000-04:00
1378983,1295f9fe-05e5-4f04-82ac-4b90ef454df5,Q1,NOSSAMAN LLP,29846,"AMERISOURCEBERGEN CORPORATION (FORMERLY ""AMERISOURCEBERGEN SPECIALTY GROUP"")",2013,first_quarter,PHA,(H.R.800) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.  Pharmaceutical pedigree anti-counterfeiting legislation.  Legislation pertaining to drug manufacturing shortages.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-18T16:48:27.007000-04:00
1379326,5844f3fa-3dd0-48fc-a8fe-688313708990,Q1,KAISER FOUNDATION HEALTH PLAN INC.,21027,KAISER FOUNDATION HEALTH PLAN INC,2013,first_quarter,PHA,"S 2002 - Online Pharmacy Safety Act: To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet pharmacies.
Sponsor: Feinstein (CA)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,260000,0,0,2013-04-18T18:33:14.157000-04:00
1379588,2e76666b-3130-49e6-9e24-c84c9c818e56,Q1,"BLUESTONE STRATEGIES, LLC",400658980,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2013,first_quarter,PHA,"Pharmacy Act, Genergic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-18T22:51:25.957000-04:00
1379872,19767c1a-9e74-43bb-98a8-e0f99a287165,Q1,WINSTON & STRAWN LLP,41682,FRESENIUS KABI USA (FORMERLY KNOWN AS APP PHARMACEUTICALS INC ),2013,first_quarter,PHA,"Represent the client on issues related to assuring a safe, reliable supply of heparin and also on patent matters, including settlements and extensions.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-19T09:50:18.763000-04:00
1380350,fa369b8b-fd48-490d-9204-a6aacfab02e9,Q1,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2013,first_quarter,PHA,"S. 622/H.R. 1407 Animal Drug User Fee Amendments of 2013;
H.R. 820 Delivering Antimicrobial Transparency in Animals Act of 2013;
Inquiries to and discussions with Federal Trade Commission on veterinary pet prescriptions.","Agriculture, Dept of (USDA),Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,120000,0,0,2013-04-19T10:51:21.577000-04:00
1380480,738a86b7-7118-4317-9ddc-d36c27873b3b,Q1,THE DUBERSTEIN GROUP INC.,12675,PHRMA INC.,2013,first_quarter,PHA,"Patent settlement between brand and generic drugs - S.Con.Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 (Vitter amendment).","HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2013-04-19T11:07:20.903000-04:00
1380644,3ae9bf8f-7511-4e25-bcff-e9e6ebda18ad,Q1,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,"ALLIED  MEDICAL SUPPLY,  INC.",2013,first_quarter,PHA,Issues affecting resellers of pharmaceutical products,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-19T11:22:25.033000-04:00
1380812,2a5b208a-5bab-4fd5-9614-f482d1aaf900,Q1,"RUBICON ADVISORS, LLC",315091,"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.",2013,first_quarter,PHA,"Physician Payment Sunshine Act S 2029
Patent Settlements H.R. 14328 .316
Affordable Healthcare Choices Act","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-19T11:35:34.177000-04:00
1380830,bdf5b631-2c6b-41c2-bd7c-d1295c626132,Q1,THE DUBERSTEIN GROUP INC.,12675,PFIZER INC.,2013,first_quarter,PHA,"Pharmaceutical issues, including track and trace, and drug reimportation.
Tampering with prescription pills - HR 486, Stop Tampering of Prescription Pills Act of 2013.
Detromethorphan abuse - S 644, PACT Act.","HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2013-04-19T11:36:40.630000-04:00
1380860,682de13f-ecb7-4243-80d8-3327ffd63aa4,Q1,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2013,first_quarter,PHA,"Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100
Affodable Health Choices Act","HOUSE OF REPRESENTATIVES,SENATE",105000,,0,0,2013-04-19T11:40:54.097000-04:00
1380870,1449365e-5ac8-4051-9bce-dc119380ba7d,Q1,"RUBICON ADVISORS, LLC",315091,WATSON PHARMACEUTICALS INC,2013,first_quarter,PHA,"Patent Reform H.R. 1908, Import Safety Act H.R. 2100     Affordable Health Choices Act
Patent Settlements H.R. 1432 S 316
Generic Biologics S 1685 H.R. 5629
Physician Payment Sunshine Act S 2029","HOUSE OF REPRESENTATIVES,SENATE",98000,,0,0,2013-04-19T11:42:57.250000-04:00
1381031,8bf56eba-0b68-48ef-a5c8-56ad3163cf8b,Q1,AMERICAN ASSOCIATION OF NURSE PRACTITIONERS,401040928,AMERICAN ASSOCIATION OF NURSE PRACTITIONERS,2013,first_quarter,PHA,"Legislation and policies relating to:
FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substanceH.R. 1285  To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug
S. 621 - Safe Prescribing Act","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office",,43392,0,0,2013-04-19T12:10:55.853000-04:00
1381074,f654aba0-abfe-4d76-aa7f-9458d262193a,Q1,"RUBICON ADVISORS, LLC",315091,STATE MUTUAL INSURANCE COMPANY,2013,first_quarter,PHA,Pharmacy - Compounding,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2013-04-19T12:16:11.367000-04:00
1381154,19719f3d-4c76-4895-a601-1f87523356f8,Q1,340B HEALTH,316434,340B HEALTH,2013,first_quarter,PHA,Discussing the importance of the 340B drug discount program and improving program oversight.,"Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,187253,0,0,2013-04-19T12:25:38.953000-04:00
1381283,873fb633-a7b0-43bb-ad32-59656212ca6c,Q1,ARNOLD & PORTER KAYE SCHOLER LLP,4301,INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS,2013,first_quarter,PHA,Issues related to the regulation of the practice of pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-04-19T12:43:26.280000-04:00
1381681,6557139e-d285-4dfd-a35f-683dc1a442d6,Q1,NATIONAL PATIENT ADVOCATE FOUNDATION,28311,NATIONAL PATIENT ADVOCATE FOUNDATION,2013,first_quarter,PHA,"Specialty Tiers, Biosimilars","Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,38073,0,0,2013-04-19T13:35:58.567000-04:00
1381846,8de5379e-d56f-4d03-8cc3-bbd48cae9536,Q1,GOLDEN HORIZONS,44275,GOLDEN HORIZONS,2013,first_quarter,PHA,"Monitor and advocate regarding pharmacy issues impacting Long Term Care and Post Acute Care providers and patients.  
H.R. 1285/S. 621 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug;
H.R. 1366 - Stop Oxy Abuse Act of 2013","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Labor Relations Board (NLRB),Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office",,94997,0,0,2013-04-19T13:49:57.053000-04:00
1381848,8917cb74-b1fe-44a6-91c1-bf56d0d1d422,Q1,BLANK ROME GOVERNMENT RELATIONS,6325,WALGREEN CO,2013,first_quarter,PHA,"Issues relating to requiring Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2013-04-19T13:49:58.537000-04:00
1381946,a51c31b2-6e45-4dc8-b1df-f33aba22a15b,Q1,CAPITOLOGIC LLC,400426045,"BULALAW, LLC",2013,first_quarter,PHA,Federal funding of illegal prescription drug market interventions,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute of Justice,Office of Justice Program,SENATE",,,0,0,2013-04-19T13:55:32.347000-04:00
1382387,6bc67b16-871c-4cc1-a402-1ea5513660dc,Q1,FTI GOVERNMENT AFFAIRS,401054971,AMERICAS HEALTH INSURANCE PLANS (AHIP),2013,first_quarter,PHA,"H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2013-04-19T14:30:33.460000-04:00
1382872,9ddb652a-3f12-49db-a286-bd9084df865d,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2013,first_quarter,PHA,"**see addendum pageImportation of prescription drugs 
Drug Abuse (S. 348), Hydrocodone Rescheduling (H.R. 1285, S. 621), Dextromethorphan (S. 644)
Drug Shortages 
Rx Pedigree 
Prescription Drug Monitoring Program  
Counterfeit Drugs 

***, no specific bills, supply chain integrity, prescription drug abuse","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2013-04-19T15:00:39.807000-04:00
1382982,fe421406-5eef-464d-ac20-0a21542fa5cd,Q1,"FIERCE, ISAKOWITZ & BLALOCK",44812,RICHIE'S SPECIALTY PHARMACY,2013,first_quarter,PHA,Pharmacy Compounding,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2013-04-19T15:07:16.717000-04:00
1383018,64157c7f-f13b-4427-9721-2b637377f740,1T,"FIERCE, ISAKOWITZ & BLALOCK",44812,"SUCAMPO PHARMACEUTICALS, INC.",2013,first_quarter,PHA,General FDA Issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2013-04-19T15:09:21.827000-04:00
1383076,e6f2ebf5-256d-48bf-bbb8-dcd79fe5e97a,Q1,"RASKY PARTNERS, INC.",297410,ELI LILLY AND CO,2013,first_quarter,PHA,"Monitor biologics related issues, Medicare Part D","HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2013-04-19T15:12:51.997000-04:00
1383181,cf2e49bf-176d-490d-a788-9bd61e1ac087,Q1,"BOCKORNY GROUP, INC.",289773,CVS HEALTH INC,2013,first_quarter,PHA,"Issues related to prescription drug abuse and drug supply chain safety.
H.R. 1188, Preserving Our Hometown Independent Pharmacies Act of 2013","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-04-19T15:21:38.617000-04:00
1383344,b7989007-c168-4551-9025-51759dc8085b,Q1,UNIVERSITY OF CONNECTICUT,39382,UNIVERSITY OF CONNECTICUT,2013,first_quarter,PHA,"Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2014, Monitor FDA salaries and expense issues; and extramural research.","Education, Dept of,HOUSE OF REPRESENTATIVES,SENATE",,62000,0,0,2013-04-19T15:29:37.737000-04:00
1383421,c548a12a-0b7f-4971-8c21-d1a87899322f,Q1,BRAVO GROUP,296293,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2013,first_quarter,PHA,"Biopharmaceutical issues including:  social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.","HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2013-04-19T15:34:07.573000-04:00
1383557,1e211df7-17b7-464f-af19-8f73d5795c30,Q1,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2013,first_quarter,PHA,General Pharmacy Issues,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2013-04-19T15:40:56.133000-04:00
1383594,ba8574dc-c2fb-42fb-812f-ece2e84cac09,Q1,LNE GROUP,308811,OHIOGUIDESTONE (FORMALLY KNOWN AS GUIDESTONE),2013,first_quarter,PHA,Lobbied on pharmacy issues,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2013-04-19T15:42:10.380000-04:00
1383760,af04f41e-668c-4364-b983-99692cd15781,Q1,MCDERMOTT WILL & SCHULTE LLP,24338,ISIS PHARMACEUTICALS,2013,first_quarter,PHA,Health care and patent legislation to ensure the protection of life-saving medical research and development.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2013-04-19T15:51:10.453000-04:00
1383779,a07aee24-dac4-4b18-8c8b-67deedf9277f,Q1,LNE GROUP,308811,INTRINSIQ MATERIALS,2013,first_quarter,PHA,Lobbied on pharmacy issues,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2013-04-19T15:52:16.547000-04:00
1383796,982f7d75-4c5f-4044-b37d-70f8da8a2f68,Q1,AMERICAN ACADEMY OF FAMILY PHYSICIANS,1342,AMERICAN ACADEMY OF FAMILY PHYSICIANS,2013,first_quarter,PHA,"No Bill Number,  National Physician Payment Transparency program, Continuing Medical Education reporting requirements.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,White House Office",,649304,0,0,2013-04-19T15:52:22.343000-04:00
1383955,bdd722be-a021-4bc0-82e8-15e0d944d1cd,Q1,APOTEX CORP.,310973,APOTEX CORP.,2013,first_quarter,PHA,"S. 504, The Fair and Immediate Release of Generics Act, relating to market blockages caused by parked 180 day exclusivity periods
S. 214, The Preserve Access to Affordable Pharmaceuticals Act, relating to the legality of ""reverse payment"" patent settlements
Federal Trade Commission v. Actavis Supreme Court Case  No. 12-416, relating to federal policy on ""reverse payment"" settlementsFederal legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing

Actelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc.,      United States District Court for the District of New Jersey, case 1:12-cvi-05743-NLH-AMD, relating to federal legislation regarding the provision of brand drug products by brand manufacturers to generic manufacturers for development testing

Federal legisation relating to the establishment of a federal track and trace system for pharmaceuticals

Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals","HOUSE OF REPRESENTATIVES,SENATE",,200000,0,0,2013-04-19T16:00:11.443000-04:00
1384211,4dd99918-85fc-44c2-ae2d-3809d4ef6486,Q1,TAUZIN STRATEGIC NETWORKS,400786367,"ENDO PHARMACEUTICALS, INC.",2013,first_quarter,PHA,Issues relating to incentives for tamper-resistant forumulations,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2013-04-19T16:18:33.617000-04:00
1384260,65f9ca94-3e6f-4a6f-aeae-4fc2c96955fd,Q1,WALGREEN COMPANY,309071,WALGREEN COMPANY,2013,first_quarter,PHA,Issues related to pharmacy prescription compounding and Food and Drug Administration oversight.  No legislation.,"HOUSE OF REPRESENTATIVES,SENATE",,590000,0,0,2013-04-19T16:20:03.803000-04:00